Arpit Chhabra։ Heading Toward More Personalized, Adaptive, and Response-Based Care in Radioligand Therapy
Arpit Chhabra, Co-Founder of Bridge Oncology, shared a post on LinkedIn: “This GE HealthCare and Mayo Clinic collaboration is a great example of where radioligand therapy is heading: more…
Read the full articleYou might also wanna read
GE HealthCare and Mayo Clinic launch theranostics study to personalize prostate cancer treatment
CHICAGO, Ill. and ROCHESTER, Minn. — GE HealthCare and Mayo Clinic today announced the MI-BET (Molecular Imaging Biomarker-Based End of Ther
mayocl.in·2d ago
Personalized Treatment Strategies for HER2-Positive Gastroesophageal Adenocarcinoma
Stay current with evolving strategies for HER2-positive gastroesophageal adenocarcinoman (GEA). Improve your practice with continuing educat
mdsc.pe·20d ago
Beyond the abstract: Clinigen exec discusses the value of patient connection
The company's commercial development director discusses the purpose in connecting patients with critical medicines.
Mayo Clinic aligns Berg Innovation Exchange with Business Development to accelerate healthcare innovation
Mayo Clinic’s Berg Innovation Exchange and Business Development unite expertise in collaboration, commercialization and venture creation to
mayocl.in·9d agoFate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease
“We were not expecting to see clinical responses so early,” Vaneet Sandhu, M.D., rheumatologist and vice president of clinical development a
Modelling Study Projects Rapid Growth in Radioligand Therapy Patient Populations Across EU and UK Healthcare Systems
The expected uptake of RLTs in EU healthcare systems over the coming decade may overwhelm available treatment capacity, even in countries wi
Comments
Sign in to join the conversation.
No comments yet. Be the first.